CSM Protect: Efficacy of Riluzole in Patients with Cervical Spondylotic Myelopathy Undergoing Surgical Treatment. A Multi-Center Double Blind Randomized Controlled Trial

The primary objective of this study is to evaluate whether sodium-glutamate antagonist riluzole in a dose of 50mg BID 14 days prior to the surgery and 28 days following the surgery is superior to placebo in achieving better neurological outcomes in patients undergoing surgical decompression for moderate or severe cervical spondylotic myelopathy. Secondary objectives are to evaluate differences between the investigational and the control group as measured by pain, functional and quality of life outcomes, health utilities, and adverse events.

Principal Investigator:

Michael G. Fehlings
University of Toronto
Toronto, Ontario, Canada

Collaborators:
- Tim Yoon, Emory University, Atlanta, GA
- Bradley Jacobs, University of Calgary, Canada
- Christopher Shaffrey, University of Virginia, Charlottesville, VA
- Paul Arnold, University of Kansas, Kansas City, KS
- Jason Wilson, Louisiana State University, USA
- H. Francis Farhadi, Ohio State University, Columbus, USA
- Alan S. Hilibrand, Rothman Institute, Philadelphia, USA
- Ahmad Nassr, Mayo Clinic, Rochester, MN
- Daryl Fourney, University of Saskatchewan, Saskatoon, Canada
- Darrel Brodke, University of Utah, USA
- Henry Ahn, St. Michael's Hospital, University of Toronto, Canada
- Mike Kelly, Washington University, St. Louis, MO
- Praveen Mummaneni, University of California San Francisco, USA
- James Harrop, Thomas Jefferson University, USA
Contact information:

Chi Lam  
Project Manager  

AOSpine North America  
1700 Russell Rd.  
Paoli, PA 19301  
Tel: + 303 250 3395  

Clam@aospine.org